Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

Inclusion Criteria:

   - Diagnosis of extracranial Ewing sarcoma or peripheral primitive neuroectodermal tumor
   of bone or soft tissue:

      - Newly diagnosed disease

      - Disease confirmed by biopsy only with no attempt at complete or partial resection

         - Unplanned excision allowed provided adequate imaging was obtained prior to
         surgery and incompletely resected disease is controlled by local therapy

      - No esthesioneuroblastoma

   - Localized disease, including any of the following sites:

      - Chest wall tumors with ipsilateral pleural effusions, ipsilateral positive
      pleural fluid cytology, or ipsilateral pleural based secondary tumor nodules;

         - No contralateral pleural effusions or pleural nodules

      - Regional lymph nodes that are clinically suspicious or confirmed by biopsy

         - No distant lymph node metastases

      - Extra-dural tumors arising in the bony skull

         - No tumors arising in the intra-dural soft tissue or the intra-dural region
         of the spine

   - No evidence of metastatic disease, defined as any of the following:

      - Lesions that are discontinuous from the primary tumor

      - Lesions that are not regional lymph nodes

      - Lesions that do not share a body cavity with the primary tumor

   - No evidence by CT scan of metastatic lung disease, defined as any of the following:

      - One pulmonary nodule > 1 cm in diameter or more than one nodule > 0.5 cm diameter

         - Pulmonary nodules that are resected and are not found to be metastatic Ewing
         sarcoma are allowed

      - Biopsy proven solitary nodules measuring 0.5 to 1.0 cm or multiple nodules
      measuring 0.3 to 0.5 cm

         - Solitary nodules measuring < 0.5 cm or multiple nodules measuring < 0.3 cm
         are allowed unless biopsy proven to be metastatic (biopsy is not required)

   - Karnofsky performance status (PS) 0-2 (>= 16 years old) OR Lansky PS 0-2 (< 16 years
   old)

   - Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum
   creatinine based on age/gender as follows:

      - 1 month to < 6 months old (males and females 0.4 mg/dL)

      - 6 months to < 1 year old (males and females 0.5 mg/dL)

      - 1 to < 2 years old (males and females 0.6 mg/dL)

      - 2 to < 6 years old (males and females 0.8 mg/dL)

      - 6 to < 10 years old (males and females 1.0 mg/dL)

      - 10 to < 13 years old (males and females 1.2 mg/dL)

      - 13 to < 16 years old (males 1.5 mg/dL and females 1.4 mg/dL)

      - >= 16 years old (males 1.7 mg/dL and females 1.4 mg/dL)

   - AST or ALT < 2.5 times ULN for age

   - Total bilirubin =< 1.5 times upper limit of normal (ULN) for age

   - Shortening fraction of >= 27% by ECHO or ejection fraction of >= 50% by radionuclide
   angiogram (MUGA)

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

   - No prior chemotherapy or radiotherapy

   - No concurrent pegfilgrastim (Neulasta) or sargramostim (GM-CSF)

   - No other concurrent cancer chemotherapy or immunomodulating agents, including
   steroids, unless used as an antiemetic